Scope and Claims Analysis for US Patent 9,539,302 (Desmopressin Intranasal Low-Blood-Concentration Spray with Emulsion + Permeation Enhancer)
US 9,539,302 claims an intranasal desmopressin spray device and plume geometry intended to deliver “low” systemic desmopressin exposure (to reduce hyponatremia risk) using a specific droplet architecture (conical plume with axial apex at the nozzle), a droplet density gradient, and a defined low dose range, where the droplets are oil-in-water emulsion droplets containing desmopressin and a permeation enhancer. Independent claim 1 anchors the scope; dependent claims refine plume geometry, target blood concentration thresholds by patient weight, and specify the permeation enhancer as cyclopentadecanolide, plus example-like dose embodiments.
Core takeaway: the enforceable claim boundaries are anchored on (i) device-and-plume physical delivery structure, (ii) dose quantity expressed as “desmopressin amount within the droplets” in the conical plume (not just nominal spray metering), and (iii) droplet composition (oil-in-water emulsion + permeation enhancer), with optional hard targets for blood concentration outcomes and a specific permeation enhancer.
What does US Patent 9,539,302 claim in intranasal desmopressin delivery?
Direct answer: Claim 1 covers an intranasal spray device with a nozzle that emits a plume over a time interval. The plume is defined as a conical volume of moving droplets with a droplet-density gradient increasing in a direction normal to the cone axis. The droplets together carry a defined low amount of desmopressin (0.05 μg to 5.0 μg) and the droplets comprise an oil-in-water emulsion plus a permeation enhancer.
Independent claim 1: claim-structure breakdown (enforceability levers)
Claim 1 is drafted as a combination claim requiring all elements below:
-
Delivery platform
- “An intranasal spray device”
- Includes “a reservoir disposed therein a composition comprising desmopressin”
- Includes “an outlet… comprising a nozzle”
-
Plume delivery physics and geometry
- “nozzle which dispenses a desmopressin dose in the form of a plume”
- plume is emitted “over a time interval”
- the plume comprises:
- “a volume of moving droplets”
- “defining a conical volume having a central axis and an apex at the nozzle”
- plume droplet density gradient:
- “droplet density… within the conical volume increases in a direction normal to the axis”
- This is a structural/kinematic requirement tied to measurable plume properties.
-
Dose amount tied to the plume
- “the droplets together comprising between about 0.05 μg and 5.0 μg desmopressin”
- This frames dose as the amount contained in “the droplets together” within the plume geometry, not merely a metered dose irrespective of plume.
-
Functional objective
- “to produce safe antidiuresis in human patients”
- “to minimize the likelihood… hyponatremia”
- Function appears as intended-use language attached to the device claim; under US practice, it still constrains claim interpretation when tied to specific structural limitations (it is tethered to the low systemic exposure strategy through the specific plume/dose/composition).
-
Droplet composition
- droplets “further comprise”
- (a) “an oil-in-water emulsion”
- (b) “a permeation enhancer”
What is most likely to drive infringement analysis:
- the ability to show that the competitor’s nozzle produces a conical plume with a droplet density that increases in a direction normal to the cone axis; and
- quantifying desmopressin mass in the plume droplets falling within 0.05–5.0 μg; and
- showing the droplets are an oil-in-water emulsion containing a permeation enhancer.
How narrow is the dose limitation (0.05–5.0 μg) in claim 1?
Direct answer: The claim 1 dose range is a numeric microgram band (0.05 to 5.0 μg desmopressin carried in the plume droplets). Dependent claims include specific embodiments around 1.5 μg and 0.75 μg, and dependent claim 3/4/5 tie delivery to blood concentration thresholds.
Dose-range consequences for design-around
- Outside the numeric band: delivering >5.0 μg in the plume droplets likely avoids claim 1, but only if the “droplets together” accounting aligns with the claimed measurement approach.
- At the low end: delivering <0.05 μg may also avoid literal claim 1. Practical risk is measurement variability and “about” language.
- “About”: the claim includes “about 0.05 μg” and “about 5.0 μg.” That can expand the literal range slightly beyond strict boundaries. Claim construction typically treats “about” as not sharply fixed.
Dependent claim numeric embodiments that tighten the profile
- Claim 8: “about 1.5 μg desmopressin.”
- Claim 9: “about 0.75 μg desmopressin.”
These are narrower than claim 1 and can matter if a challenger’s product uses those specific dose sizes.
What plume geometry requirements exist, and how could they be measured?
Direct answer: The nozzle emits droplets forming a conical volume with an apex at the nozzle; within that cone, droplet density increases in a direction normal to the cone axis.
Key geometry/physics elements
-
Conical volume with central axis and apex at the nozzle
- This defines the spatial plume region that must be characterized.
-
Droplet density gradient
- “droplet density (number of droplets per unit volume) within the conical volume increases in a direction normal to the axis”
- The gradient direction is crucial: it is not merely “more dense further away” but “in a direction normal to the axis.”
Practical implications for invalidity/infringement
- Competitors can attempt to argue plume structure differs (e.g., uniform droplet density, different cone angle, different density gradient direction, or different conical segmentation).
- The patent’s enforceability often turns on how “droplet density” and “increases in a direction normal to the axis” are interpreted, including how plume volume is delimited.
What formulation scope is required: oil-in-water emulsion + permeation enhancer
Direct answer: Claim 1 requires droplets comprising both an oil-in-water emulsion and a permeation enhancer.
Formulation elements
- Oil-in-water emulsion is required.
- This excludes purely aqueous solutions without an emulsion system, unless a competitor’s system is argued to be an emulsion in the relevant sense.
- Permeation enhancer is required.
- The claim does not restrict the enhancer in claim 1.
Dependent claim 7 tightens permeation enhancer identity
- Claim 7: permeation enhancer “comprises a cyclopentadecanolide.”
That dependent claim provides a stronger hook for competitors that use cyclopentadecanolide specifically. It also indicates that cyclopentadecanolide is a central species likely supported by description/examples.
Do claims 3–5 create outcome-based blood concentration limits that further constrain infringement?
Direct answer: Yes. Claims 3–5 require the plume to be effective to deliver transmucosally sufficient desmopressin to achieve blood concentration thresholds, with thresholds progressively lowered.
Claim 3 (patient-weight specific target)
- For patients weighing 70 kg or 35 kg:
- effective to produce “a desmopressin blood concentration less than 18 pg/ml.”
Claim 4
Claim 5
How to read these constraints
- The language is “plume is effective to produce” a blood concentration threshold. That imports performance-based limitation tied to clinical PK outcomes.
- In infringement analysis, the central question becomes whether the accused formulation/device combination achieves the threshold in the relevant patient-weight groups (or equivalently under claim construction that treats “effective to” as an inherent property of the claimed structure).
Design-around strategy suggested by the claim text:
- competing products might maintain similar plume structure but shift systemic exposure above the thresholds, either by dose, formulation, or device delivery characteristics. However, if structure/amount/composition still match claim 1, the performance limitation could still be met depending on clinical data.
How does claim 2 further limit plume shape near the nozzle?
Direct answer: Claim 2 requires that an axial cross section of the conical plume at a surface about 3 cm or less from the nozzle apex describes an annular disk of droplets.
Interpretation of claim 2
- It specifies the cross-sectional shape near the apex:
- “annular disk of droplets”
- Spatial limitation:
- cross section taken at “a surface about 3 cm or less” from the apex.
Practical impact
- This adds another physical constraint potentially measurable via imaging/spray characterization.
- A competitor could attempt to keep the general conical plume but produce a different near-nozzle cross-sectional droplet distribution (e.g., more filled core rather than an annular disk).
What is the overall patent claim “scope map” across device, plume, dose, composition, and outcome?
Scope stratification by claim type
| Claim |
Category |
Hard structural/numeric limits |
Performance/outcome limits |
Extra specificity |
| 1 |
Independent |
Intranasal nozzle plume: conical volume with apex at nozzle; droplet density increases in direction normal to axis; droplets carry 0.05–5.0 μg; droplets are oil-in-water emulsion + permeation enhancer |
“safe antidiuresis” and hyponatremia minimization (intended objective) |
Broad permeation enhancer identity (any permeation enhancer) |
| 2 |
Dependent |
Near-apex axial cross section at ~3 cm or less is “annular disk of droplets” |
None |
Plume shape constraint |
| 3 |
Dependent |
Same as claim 1 |
Blood concentration <18 pg/ml for 70 kg or 35 kg |
Adds patient-weight threshold |
| 4 |
Dependent |
Same as claim 1 |
Blood concentration <15 pg/ml |
Tightens threshold |
| 5 |
Dependent |
Same as claim 1 |
Blood concentration <10 pg/ml |
Tightens threshold |
| 6 |
Dependent |
Same as claim 1 |
None |
Narrows dose to 0.2–5.0 μg |
| 7 |
Dependent |
Same as claim 1 |
None |
Permeation enhancer comprises cyclopentadecanolide |
| 8 |
Dependent |
Same as claim 1 |
None |
Dose “about 1.5 μg” |
| 9 |
Dependent |
Same as claim 1 |
None |
Dose “about 0.75 μg” |
How many distinct inventive “pillars” are embedded in US 9,539,302’s claim set?
Direct answer: At least four pillars:
- Low systemic exposure targeting via low dose in plume droplets (0.05–5.0 μg) and explicit blood concentration thresholds (claims 3–5).
- Plume structure using a conical droplet field with a droplet-density gradient directionally defined.
- Near-nozzle droplet ring formation (annular disk within ~3 cm) in claim 2.
- Formulation composition using oil-in-water emulsion droplets with a permeation enhancer, including cyclopentadecanolide in claim 7.
This multi-pillar architecture creates multiple potential entry points for both infringement and validity arguments, but it also makes the claims less likely to be met accidentally by a different design that misses even one pillar.
What competitors or product attributes would most likely intersect this patent’s scope?
Direct answer: The highest overlap is with intranasal desmopressin products (or delivery variants) that:
- use an intranasal nozzle generating a conical droplet plume with increasing droplet density normal to the cone axis; and
- dose within 0.05–5.0 μg desmopressin per administration; and
- use an oil-in-water emulsion formulation with permeation enhancers (especially cyclopentadecanolide); and
- achieve blood concentrations under 18 pg/ml (and potentially 15 or 10 pg/ml) at patient weights of 70 kg or 35 kg.
Because the claim is device-and-plume specific, “same API” alone is not enough for infringement. The product must replicate the physical delivery and formulation combination.
How could the patent be used in litigation or licensing leverage?
Direct answer: This patent supports both standard Orange Book-style drug-device formulation bargaining (if listed) and more targeted licensing around:
- low-dose intranasal desmopressin delivery regimes designed to reduce hyponatremia risk; and
- particular plume/droplet architecture and enhancer systems.
Likely claim attack surfaces in US litigation
- Claim construction of “droplet density increases in a direction normal to the axis” and “annular disk of droplets.”
- Obviousness based on prior spray devices, prior desmopressin intranasal formulations, and known permeation enhancers in intranasal systems, combined with “low dose” PK targeting.
- Enablement/written description for:
- the measurable plume characteristics; and
- the specific blood concentration thresholds for 70 kg and 35 kg groups; and
- cyclopentadecanolide emulsion systems.
(Notes: an explicit invalidity portfolio cannot be generated from the claim text alone.)
What is the commercial and regulatory relevance of the claimed hyponatremia-risk objective?
Direct answer: The claim’s low systemic exposure targets (blood concentration thresholds under 18/15/10 pg/ml) are directly aligned with minimizing hyponatremia risk in desmopressin therapy, making the claims commercially meaningful where regulators and prescribers track PK exposure and safety margins.
Key Takeaways
- US 9,539,302 is a device-plume-formulation hybrid claim: it requires an intranasal nozzle producing a conical droplet plume with a directionally increasing droplet density, delivering 0.05–5.0 μg desmopressin in the plume droplets.
- The droplet formulation must be an oil-in-water emulsion containing a permeation enhancer; cyclopentadecanolide is explicitly claimed in dependent claim 7.
- Dependent claims add near-nozzle geometry (annular disk at ≤3 cm), dose narrowing (0.2–5.0 μg), and performance-based PK thresholds tied to patient weights (blood desmopressin <18/15/10 pg/ml).
- The strongest infringement focus is a product that matches all pillars simultaneously: plume structure + low microgram dosing + emulsion/enhancer composition + (for certain claims) achieving the blood concentration thresholds.
FAQs
1. What does “droplets together comprising between about 0.05 μg and 5.0 μg desmopressin” mean for infringement accounting?
It ties the claimed dose to the total desmopressin mass carried by the droplets within the defined conical plume volume, not just the device’s nominal actuation amount.
2. If a competitor uses an oil-in-water emulsion but a permeation enhancer other than cyclopentadecanolide, which claims remain in play?
Claim 1 remains potentially in play because it requires a permeation enhancer generally; claim 7 would not be met unless cyclopentadecanolide is present.
3. How could a competitor design around the “increasing droplet density normal to the axis” requirement?
By altering spray physics to produce a plume where droplet density does not increase in the specified normal direction within the conical volume (e.g., more uniform density, different gradient orientation, or different cone/cross-section behavior).
4. Are the blood concentration limits in claims 3–5 part of infringement proof?
Yes. Those claims require the plume to be effective to produce blood concentrations below specified pg/ml thresholds for the stated patient weights.
5. Does claim 2 make the patent easier or harder to design around?
Harder for an accused product to meet claim 2 literally, because it adds a near-apex cross-sectional shape constraint (annular droplet disk within ~3 cm), but claim 1 still provides broader coverage even if claim 2 is missed.
References
- US Patent 9,539,302.
